Maria Laura Stromillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Laura Stromillo has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Federico
University of Siena
4 shared publications - Nicola De Stefano
Department of Medicine, Surgery and Neuroscience, University of Siena, Italy
4 shared publications A. Federico
Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
2 shared publicationsA. Giorgio
Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
2 shared publicationsL. Guidi
2 shared publicationsM T Dotti
2 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (6) , e70215
Comparative Analysis of SiMoA and Ella Immunoassay Platforms for Measuring Serum Neurofilament Light Chain Levels in ATTRv With Polyneuropathy and Presymptomatic Carriers
Background: Neurofilament light chains (NfL) represent reliable serum biomarkers of neuroaxonal injury. Due to their low serum levels, precise detection methods are critical. This study aimed to scrutinize the comparability of two techniques: Single Molecule Array (SiMoA) and Ella automated immunoassay, analyzing serum NfL levels in ATTRv presymptomatic subjects and polyneuropathy patients.Methods: Blood samples were processed and analyzed using commercial Ella and SiMoA kits. Statistical analysis included the Wilcoxon signed‐rank test, Spearman correlation, Bland–Altman, and Passing‐Bablok regression. ANCOVA models were used to compare NfL levels between cohorts.Results: The study measured serum NfL levels in 55 symptomatic and 55 presymptomatic ATTRv subjects. Median NfL concentrations were significantly higher with Ella (median 27.5 pg/mL) than SiMoA (median 15.9 pg/mL). Both methods showed a strong positive correlation (r = 0.8, p < 0.001), but Ella overestimated NfL by 42%. Bland–Altman analysis revealed a mean bias of 15.4 pg/mL, with limits of agreement between −41.1 and 72.0 pg/mL. The slope of the Passing–Bablok regression line was 0.58, and the intercept was 3.48 pg/mL, suggesting that the Ella platform tends to overestimate NfL concentrations compared to the SiMoA platform, especially at higher concentrations. Both methods effectively distinguished presymptomatic from symptomatic patients (p < 0.001 for both).Conclusions: Our findings underscore that both platforms are effective in measuring serum NfL, with Ella consistently overestimating, especially at higher concentrations. The difference between the two platforms must be taken into account when deeming the concentrations as pathological or normal, as well as when conducting longitudinal studies.
- 3 June 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (6) , e70215
Open AccessComparative Analysis of SiMoA and Ella Immunoassay Platforms for Measuring Serum Neurofilament Light Chain Levels in ATTRv With Polyneuropathy and Presymptomatic Carriers
Background: Neurofilament light chains (NfL) represent reliable serum biomarkers of neuroaxonal injury. Due to their low serum levels, precise detection methods are critical. This study aimed to scrutinize the comparability of two techniques: Single Molecule Array (SiMoA) and Ella automated immunoassay, analyzing serum NfL levels in ATTRv presymptomatic subjects and polyneuropathy patients.Methods: Blood samples were processed and analyzed using commercial Ella and SiMoA kits. Statistical analysis included the Wilcoxon signed‐rank test, Spearman correlation, Bland–Altman, and Passing‐Bablok regression. ANCOVA models were used to compare NfL levels between cohorts.Results: The study measured serum NfL levels in 55 symptomatic and 55 presymptomatic ATTRv subjects. Median NfL concentrations were significantly higher with Ella (median 27.5 pg/mL) than SiMoA (median 15.9 pg/mL). Both methods showed a strong positive correlation (r = 0.8, p < 0.001), but Ella overestimated NfL by 42%. Bland–Altman analysis revealed a mean bias of 15.4 pg/mL, with limits of agreement between −41.1 and 72.0 pg/mL. The slope of the Passing–Bablok regression line was 0.58, and the intercept was 3.48 pg/mL, suggesting that the Ella platform tends to overestimate NfL concentrations compared to the SiMoA platform, especially at higher concentrations. Both methods effectively distinguished presymptomatic from symptomatic patients (p < 0.001 for both).Conclusions: Our findings underscore that both platforms are effective in measuring serum NfL, with Ella consistently overestimating, especially at higher concentrations. The difference between the two platforms must be taken into account when deeming the concentrations as pathological or normal, as well as when conducting longitudinal studies.
- 1 July 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 42, 102059
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study
- 1 July 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 42, 102059
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study
- 1 January 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 27, 294-297
Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis
- 1 January 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 27, 294-297
Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis
- 1 November 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 26, 71-73
The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study
- 1 November 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 26, 71-73
The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study
- Open Access
- 29 September 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 38 (1) , 18-24
Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study
BACKGROUND AND PURPOSE: The structural MR imaging correlates of cognitive impairment in multiple sclerosis are still debated. This study assessed lesional and atrophy measures of white matter and gray matter involvement in patients with MS acquired in 7 European sites to identify the MR imaging variables most closely associated with cognitive dysfunction. MATERIALS AND METHODS: Brain dual-echo, 3D T1-weighted, and double inversion recovery scans were acquired at 3T from 62 patients with relapsing-remitting MS and 65 controls. Patients with at least 2 neuropsychological tests with abnormal findings were considered cognitively impaired. Focal WM and cortical lesions were identified, and volumetric measures from WM, cortical GM, the hippocampus, and deep GM nuclei were obtained. Age- and site-adjusted models were used to compare lesion and volumetric MR imaging variables between patients with MS who were cognitively impaired and cognitively preserved. A multivariate analysis identified MR imaging variables associated with cognitive scores and disability. RESULTS: Twenty-three patients (38%) were cognitively impaired. Compared with those with who were cognitively preserved, patients with MS with cognitive impairment had higher T2 and T1 lesion volumes and a trend toward a higher number of cortical lesions. Significant brain, cortical GM, hippocampal, deep GM nuclei, and WM atrophy was found in patients with MS with cognitive impairment versus those who were cognitively preserved. Hippocampal and deep GM nuclei atrophy were the best predictors of cognitive impairment, while WM atrophy was the best predictor of disability. CONCLUSIONS: Hippocampal and deep GM nuclei atrophy are key factors associated with cognitive impairment in MS. These MR imaging measures could be applied in a multicenter context, with cognition as clinical outcome.
- 29 September 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 38 (1) , 18-24
Open AccessHippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study
BACKGROUND AND PURPOSE: The structural MR imaging correlates of cognitive impairment in multiple sclerosis are still debated. This study assessed lesional and atrophy measures of white matter and gray matter involvement in patients with MS acquired in 7 European sites to identify the MR imaging variables most closely associated with cognitive dysfunction. MATERIALS AND METHODS: Brain dual-echo, 3D T1-weighted, and double inversion recovery scans were acquired at 3T from 62 patients with relapsing-remitting MS and 65 controls. Patients with at least 2 neuropsychological tests with abnormal findings were considered cognitively impaired. Focal WM and cortical lesions were identified, and volumetric measures from WM, cortical GM, the hippocampus, and deep GM nuclei were obtained. Age- and site-adjusted models were used to compare lesion and volumetric MR imaging variables between patients with MS who were cognitively impaired and cognitively preserved. A multivariate analysis identified MR imaging variables associated with cognitive scores and disability. RESULTS: Twenty-three patients (38%) were cognitively impaired. Compared with those with who were cognitively preserved, patients with MS with cognitive impairment had higher T2 and T1 lesion volumes and a trend toward a higher number of cortical lesions. Significant brain, cortical GM, hippocampal, deep GM nuclei, and WM atrophy was found in patients with MS with cognitive impairment versus those who were cognitively preserved. Hippocampal and deep GM nuclei atrophy were the best predictors of cognitive impairment, while WM atrophy was the best predictor of disability. CONCLUSIONS: Hippocampal and deep GM nuclei atrophy are key factors associated with cognitive impairment in MS. These MR imaging measures could be applied in a multicenter context, with cognition as clinical outcome.
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P03.065
Ten-Year Brain Atrophy and Disability Changes in Patients with Multiple Sclerosis (P03.065)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P03.065
Ten-Year Brain Atrophy and Disability Changes in Patients with Multiple Sclerosis (P03.065)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P02.089
Association of Targeted Blood Biomarkers with Interferon Beta-1a Treatment Administration, Magnetic Resonance Imaging Activity, and Treatment Response (P02.089)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P02.089
Association of Targeted Blood Biomarkers with Interferon Beta-1a Treatment Administration, Magnetic Resonance Imaging Activity, and Treatment Response (P02.089)
- 19 December 2009
- Vol. 24 (3) , 159-62
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis.
Swallowing problems can complicate the course of multiple sclerosis (MS). However, no validated questionnaire for the assessment of dysphagia in MS is currently available. We previously developed a 10-item DYsphagia in Multiple Sclerosis questionnaire (DYMUS). In the present study, this questionnaire was submitted to a validation process. Thirteen Italian MS centres took part in this research in which DYMUS was administered to 1734 consecutive MS patients during routine checkups outside relapse. The questionnaire showed very good internal consistency (Cronbach's alpha = 0.914). It was then subdivided into two subscales, both of which also showed very good internal consistency: Cronbach's alpha was 0.885 for the 'dysphagia for solids' subscale and 0.864 for the 'dysphagia for liquids' subscale. The DYMUS questionnaire was found to be an easy and reliable tool for detecting dysphagia and also for the preliminary selection of patients requiring more specific instrumental analyses, and those suitable for aspiration prevention programmes.
- 19 December 2009
- Vol. 24 (3) , 159-62
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis.
Swallowing problems can complicate the course of multiple sclerosis (MS). However, no validated questionnaire for the assessment of dysphagia in MS is currently available. We previously developed a 10-item DYsphagia in Multiple Sclerosis questionnaire (DYMUS). In the present study, this questionnaire was submitted to a validation process. Thirteen Italian MS centres took part in this research in which DYMUS was administered to 1734 consecutive MS patients during routine checkups outside relapse. The questionnaire showed very good internal consistency (Cronbach's alpha = 0.914). It was then subdivided into two subscales, both of which also showed very good internal consistency: Cronbach's alpha was 0.885 for the 'dysphagia for solids' subscale and 0.864 for the 'dysphagia for liquids' subscale. The DYMUS questionnaire was found to be an easy and reliable tool for detecting dysphagia and also for the preliminary selection of patients requiring more specific instrumental analyses, and those suitable for aspiration prevention programmes.
- 1 December 2007
- Vol. 122 (5) , 558-9
Novel human pathological mutations. Gene symbol: NOTCH3. Disease: CADASIL, exon 2 mutation.
- 1 December 2007
- Vol. 122 (5) , 558-9
Novel human pathological mutations. Gene symbol: NOTCH3. Disease: CADASIL, exon 2 mutation.
- 1 November 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (5) , 360-363
Leukoencephalopathy as a rare complication of hepatitis C infection
- 1 November 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (5) , 360-363
Leukoencephalopathy as a rare complication of hepatitis C infection